Although the number of men with lymph node-positive prostate cancer has declined, it is still significant and the challenge remains on how best to treat these patients. Only long-term follow-up can give a true indication of the outcome in prostate cancer. We evaluated our experience in treating lymph node-positive prostate cancer with a median follow-up of 10.2 years. The overall 5-year survival was 78% and the 10-year survival was 56%. Length of tumor control depends on the type of treatment given. Adding androgen ablation improves the duration of control dramatically, although optimal timing is still uncertain.
Introduction
Although the frequency of node-positive prostate cancer has decreased over the last 20 years, it still affects thousands of men each year. 1 The optimal treatment of the patient with lymph node-positive prostate cancer is unknown. 2 Options range from observation to androgen ablation (AA), surgery, radiation, chemotherapy or any combination of these treatments. There are very few randomized, prospective studies to guide us and, as a result, there continues to be a wide variety of approaches. We report the treatment experience of a single institution with long-term (median 10.2 years) follow-up node-positive patients.
Materials and methods
From 1985 to 1995, 804 patients underwent exploration for radical prostatectomy (RP). A total of 86 patients (11%) were found to be node positive. Of these, 60 (70%) underwent prostatectomy and in the other 30%, surgery was aborted. Patients were then followed up or received adjuvant treatment with AA or radiation or both. Median overall follow-up was 8.8 years (range 4 months to 16.8 years) for all patients and 10.2 years (range 4-16.8 years) for surviving patients. Biochemical failure was defined as any prostate-specific antigen (PSA)40.3 ng/ml or any rise in PSA (confirmed by a second rising PSA) after reaching a nadir. For patients treated with surgery alone, if patients did not have a PSA nadir below 0.4 ng/ml, they were considered as failing from the date of the initial postoperative PSA.
The completeness of the node dissection was done at the discretion of the operating surgeon. Patients with a grossly positive node often had that node biopsied and, if positive, no further dissection was performed.
Adjuvant treatment and treatment at failure were at the discretion of the treating urologist. Not all patients received treatment for a rising PSA alone, but all patients who developed overt metastasis received AA. 'Adjuvant' radiation was used primarily in patients with a persistent PSA (median PSA 28.4). Chemotherapy was usually reserved for the time of metastatic hormone refractory disease.
Statistical methods
Time to biochemical progression and overall survival were computed using Kaplan-Meier product-limit survival curves.
Results
The median age at the time of biopsy was 65.5 years (range 44-78 years). Twelve patients did not have a pretreatment PSA level; for the remainder, the median PSA was 24 ng/ml (range 5.3-1037 ng/ml).
The majority (72%) of the patients had palpable (T2) disease. The majority were with a Gleason score of 7 or higher, and 51 (59%) were nuclear grade 3 or 4. Clinical stage, pretreatment PSA and Gleason score are shown in Table 1 . There was no difference in treatment groups for these parameters. The only factor that showed a significant variation with treatment was nodal status (Po0.001, Fisher's exact test). RP was utilized more often only when the nodal status was unilateral single, and RP plus AA and/or XRT were utilized more often for unilateral multiple or bilateral.
Sixty (70%) patients had the prostate removed. Thirty of these patients (36%) received no other immediate treatment; 22 (42%) received the addition of AA, five (16%) radiation and three (6%) AA and radiation. Adjuvant treatment was delivered to 38% of the RP patients before a postoperative PSA was obtained. Of the 26 patients in whom prostatectomy was incomplete, one received no immediate treatment and the remainder received AA (14 patients), radiation (9 patients) or both (2 patients).
Overall, 69% of the patients suffered a recurrence and 30% died with progressive disease. At last follow-up, 36% were alive without evidence of disease and 17% were alive with disease. Six percent had died of other causes with disease controlled after recurrence. The overall 5-year survival was 78% and the 10-year survival was 56%.
As shown in Table 2 , all of the patients undergoing RP without any adjuvant treatment suffered biochemical recurrence by 10 years (median 1.6 years). For the five patients who also received radiation, biochemical progression occurred much later at a median of 6.6 years. For the nine patients with radiation alone, all had a biochemical recurrence and the median time to recurrence was similar to surgery alone at 1.8 years. If AA was given alone or was added to surgery or radiation, median time to biochemical failure was 11.9 years. Although the numbers are small, in general, the results indicate that patients receiving at least two of the treatment modalities had better biochemical and overall survival than those receiving only one modality. In the evaluation of those who received only AA (14 patients), median time to biochemical failure was 8.8 years with a 5-year biochemical free survival and overall survival of 64 and 79%, respectively, and 10-year biochemical free survival and overall survival of 49 and 37%, respectively. If they had undergone RP with or without radiation and also received AA, median time to biochemical failure was 12.3 years with 5-year biochemical free survival and overall survival of 85 and 89%, respectively and 10-year biochemical failure-free survival and overall survival of 75 and 75%, respectively. A detailed statistical analysis of all the subgroups was not possible owing to sparse data, but we were able to compare the RP only group to the prostatectomy with AA and the AA only groups. Between the three groups, there is no significant difference with respect to overall survival (P-value Unilateral single  45  41  73  19  54  Unilateral multiple  16  50  75  50  54  Bilateral  25  60  88  45  58 Abbreviations: AA, androgen ablation; bFSS, biochemical (PSA) failure-free survival; OS, overall survival; PSA, prostate-specific antigen; RP, radical prostatectomy.
Lymph node positive prostate cancer GP Swanson et al comparing the three Kaplan-Meier survival curves is 0.47). However, the difference in biochemical survival (Table 2 ) among the three groups is significant (Po0.0001). The RP group is significantly different from the RP þAA group (Po0.0001) as well as the AA group (Po0.01), while the RP þAA and the AA groups are not significantly different (P ¼ 0.25). We also analyzed the outcome of traditional prognostic factors such as pretreatment PSA, Gleason's score and nodal status ( Table 2) . None of the factors predicted a significantly worse outcome. Finally, we evaluated how patients with AA at failure fared when compared with those who received AA up front. For the 41 patients who received initial AA as a component of their treatment, median time to biochemical failure was 11.9 years, while 10-year biochemical failure-free survival was 66% and 10-year overall survival was 61%. For the 44 patients who underwent prostatectomy and/or radiation, 20 received subsequent AA. Their median time to failure from their initial treatment was 1.34 years. The PSA at the time AA was started was 20.5 ng/ml (range 0.4-584 ng/ml). In these 20 patients, the median time to failure after the initiation of AA was 5.05 years (or 6.39 years overall). For them, both 10-year biochemical failure-free survival and 10-year overall survival were 49%.
Discussion
No treatment has been shown to be optimal in nodepositive prostate cancer. 2 Without large randomized studies, comparison is very tenuous because of patient selection factors. Differences in prognostic factors between the different modalities of treatment have been recognized by others. [3] [4] [5] [6] Since there are almost no prospective data, we are left with retrospective studies to try to determine how best to approach these patients. Without a clear consensus, in many practices, lymph node-positive patients are treated in a wide variety of ways. Our experience demonstrates that, and with longterm follow-up, we have fairly precise information on how these patients ultimately fare. This gives us an opportunity to evaluate our approach with regard to what has been reported by others. With the relative paucity of precise information available, this detailed analysis can give us a better idea on the approaches we should pursue.
Although there is nihilism about lymph node-positive prostate cancer, some patients do well. We saw a 36% long-term disease-free survival (median follow-up 10 years). Of those who had died in the interim, approximately half died of prostate cancer, but the other half died of intercurrent disease.
As with any uncontrolled study, the wide combination of treatment choices and associated selection biases results in a small number of patients in any specific category that just allows for general observations. What is clear in our patients is that surgery or radiation alone does not result in durable long-term control, which seems to be confirmed by previous observations. Prostatectomy alone is unlikely to offer a cure. In a case-control study comparing radical retropubic prostatectomy (RRP) to other treatments, while there was a trend to better 10-year survival with surgery, median disease-free survival was equivalent. 7 In the largest study reported, with a median follow-up of 4.1 years, 76% of the patients had failed with surgery alone. 8 The results with primary radiation therapy are similar. In the largest series, 9 5-and 10-year metastasis-free survivals were 32 and 17%, respectively, with a 10-year overall survival of 32%. In more contemporary series utilizing biochemical follow-up, the best results 10 report a 5-year biochemical disease-free survival of 77% with radiation alone. A second study utilizing a brachytherapy boost 11 showed a 5-year biochemical failure-free survival rate of 64%. Although the results of these two more recent series seem favorable, the perception of most practitioners, as confirmed by our small group of patients, is that radiation alone is not likely to result in a durable response. Our results support the findings that, as sole modalities, failure after surgery or radiation alone is high.
To improve on the less than optimal responses, some clinicians have combined surgery and radiation. The largest study included only 43 patients. 12 At a median follow-up of 86 months, PSA-based 10-year disease-free survival was 37% for patients with a single microscopic node (o5 mm foci), 25% for single node (focus45 mm) and 10% for more than one lymph node positive. This does not appear to be a dramatic improvement. Still, it seems that a small subgroup of node-positive patients do well if disease in the pelvis is controlled. Although we had only five patients who received both treatments, their median time to failure was three times longer than those who received either radiation or surgery alone. This raises the question whether adjuvant radiation can at least delay progression.
Although not curative, AA is a frequently used treatment modality, both as primary treatment and as an adjunct to other treatments.
The two largest studies 13, 14 with primary AA reported 10-year survival rates of 30 and 46%, respectively. Tenyear cause-specific survival was 45%, 14 with a 10-year biochemical failure-free survival rate of 25%. 13 Our results were similar with a 37% 10-year survival and 49% 10-year biochemical failure-free survival for AA alone. An interesting study from the European Organization for the Research and Therapy of Cancer (EORTC) randomized patients with node-positive prostate cancer patients who did not undergo prostatectomy. 15 Subjects were randomized to receive either immediate AA (119 patients) or AA at clinical (usually metastatic) progression. There was no significant difference in 5-year survival (65%). It will be interesting to see how these patients fare in the next 5 years. Overall, the results of treating node-positive prostate cancer with AA alone are comparable with those seen with surgery or radiation.
The results of combining treatments are compelling. In our series, patients who were given AA with surgery and/or radiation therapy appeared to fare the best. Whether this is due to selection factors where these patients were thought to be able to better withstand bior tri-modality treatment is uncertain. This does support a consistent observation from retrospective series. In an older series, 243 patients underwent prostatectomy and AA. 8 Ten-year clinical disease-free survival was 76% and, with a median follow-up of 49 months, 20% had died of cancer. In a more contemporary series of 147 patients Lymph node positive prostate cancer GP Swanson et al with a median follow-up of 42 months, 10-year causespecific survival was 74% and biochemical recurrencefree survival was 50%. Since most patients in these series had microscopic nodal disease, it is uncertain whether the results are really superior to patients treated with AA alone, as the latter usually have bulkier disease. Unfortunately, a randomized study comparing surgery to surgery with AA closed early (approximately 50% accrual). The trial randomized patients with RRP alone or RRP and immediate hormonal therapy. 16 Also unfortunate was that the non-hormone arm was mandated to not receive AA until it developed metastatic disease, something most urologists would not do in contemporary practice. With these limitations, there was a significant improvement in survival in the 49 men receiving immediate androgen deprivation. They experienced a 10-year overall survival of 72% and a causespecific survival of 87%. In the delayed group (51 patients), it was 49 and 57%, respectively. The outstanding question is whether there would have been a difference if the control group was treated with AA at the time of PSA progression, rather than waiting for metastatic disease.
The experience with adding hormones to radiation in node-positive patients is even more limited. In an MD Anderson Hospital (MDAH) study 13 with combined radiation and AA, 10-year disease-free survival was 80% and 10-year survival was 67%. These results are comparable to the results of RP with AA but are not too dissimilar to AA alone as discussed above. In a nonrandomized comparison at MDAH, 13 the 10-year biochemical failure-free survival for AA alone was 25% compared to 80% with combined treatment. The survival difference at 5 years was only 7%, but by 10 years, it was 19%. This may reflect the manifestation of hormone refractory prostate cancer in the AA alone cohort, and adding radiation results in more durable control of the disease in some patients.
The next question would be whether adding radiation to prostatectomy and AA would have any further advantages. One study looked at the combination of surgery, radiation and AA 17 in 54 patients and, with a median follow-up of 61 months, found a 5-year biochemical free survival of 81%. There were no local failures and only 7% of the patients died of cancer. These results were slightly better than their cohort of 98 patients treated with RRP and AA without radiation. In these 98 patients, 5-and 10-year biochemical progression-free survivals were 71 and 48%, respectively. Ten percent suffered local failure and 20% died of cancer. We had only three patients who had received all three modalities, but it is worth noting that none of them has failed. Taken as a whole, the data hint that maximizing pelvic control results in a better median survival, which appears to be true with or without AA.
There are no randomized studies that have looked at surgery or radiation with immediate AA versus those primary interventions with AA mandated at a specific point (that is rising PSA before metastatic disease). In our own series, the patients receiving delayed AA had markedly elevated PSAs, which could explain why they did not do as well as those who received it up front. It would be interesting to see if a reasonable delay in instituting AA is as effective. Others have noted that delayed use of AA is not detrimental to survival. One study 18 involved 68 node-positive patients with prostatectomy, cryosurgery, radiation or TURP. In the 30 patients who received immediate AA, median time to progression was 100 months. In those not treated immediately, AA was given at progression (at a median of 43 months) and overall survival was not different between the two groups. If substantiated, it would appear that AA, with all of its attendant morbidities, 19, 20 could be delayed until there was evidence of biochemical progression. Waiting until there is overt clinical (that is metastatic) disease might be too late as these patients usually have poor survival rate.
From this analysis, it appears that some patients with nodal metastases from prostate cancer have good longterm outcomes. Disease control is possible in some patients with surgery or radiation alone, but it is improved with the combination of the two. The standard today is to give these patients AA, either alone or with surgery and/or radiation. Long-term control is favorable, but there is much opportunity for improvement and the toxicities of long-term AA are not insignificant. A reasonable approach is to treat the prostate with surgery and/or radiation. These treatments have reasonable morbidities and could delay progression for some time. AA could then be used more judiciously at the time of PSA progression.
